Rein Therapeutics Inc. (RNTX)
NASDAQ: RNTX · Real-Time Price · USD
1.360
-0.030 (-2.16%)
At close: Dec 5, 2025, 4:00 PM EST
1.350
-0.010 (-0.74%)
After-hours: Dec 5, 2025, 6:11 PM EST
Rein Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Selling, General & Admin | 11.42 | 13.86 | 11.36 | 9.68 | 9.6 | 9.33 | |
| Research & Development | 12.35 | 14.25 | 3.99 | 17.97 | 17.01 | 11.17 | |
| Operating Expenses | 23.77 | 28.11 | 15.35 | 27.65 | 26.61 | 20.5 | |
| Operating Income | -23.77 | -28.11 | -15.35 | -27.65 | -26.61 | -20.5 | |
| Interest & Investment Income | 0.7 | 0.7 | 0.6 | - | - | - | |
| Other Non Operating Income (Expenses) | -0.36 | -0.02 | -0.09 | 0.32 | -0.01 | 0.08 | |
| EBT Excluding Unusual Items | -23.43 | -27.43 | -14.84 | -27.33 | -26.62 | -20.42 | |
| Merger & Restructuring Charges | - | - | -0.93 | - | - | - | |
| Gain (Loss) on Sale of Assets | - | - | 0.04 | - | 0.07 | 0.09 | |
| Asset Writedown | -37 | -37 | - | - | - | - | |
| Other Unusual Items | - | - | - | - | 0.39 | -0.82 | |
| Pretax Income | -60.43 | -64.43 | -15.73 | -27.33 | -26.16 | -21.16 | |
| Income Tax Expense | -1.54 | -1.54 | - | - | - | - | |
| Net Income | -58.89 | -62.88 | -15.73 | -27.33 | -26.16 | -21.16 | |
| Net Income to Common | -58.89 | -62.88 | -15.73 | -27.33 | -26.16 | -21.16 | |
| Shares Outstanding (Basic) | 24 | 18 | 5 | 5 | 4 | 2 | |
| Shares Outstanding (Diluted) | 24 | 18 | 5 | 5 | 4 | 2 | |
| Shares Change (YoY) | 71.80% | 290.09% | 1.31% | 2.23% | 154.70% | 42.11% | |
| EPS (Basic) | -2.50 | -3.51 | -3.42 | -6.02 | -5.89 | -12.14 | |
| EPS (Diluted) | -2.50 | -3.51 | -3.42 | -6.02 | -5.89 | -12.14 | |
| Free Cash Flow | -20.95 | -22.29 | -19.81 | -24.87 | -23.91 | -20.48 | |
| Free Cash Flow Per Share | -0.89 | -1.24 | -4.31 | -5.48 | -5.38 | -11.75 | |
| EBITDA | -23.77 | -28.05 | -15.23 | -27.48 | -26.48 | -20.33 | |
| D&A For EBITDA | 0 | 0.06 | 0.12 | 0.17 | 0.12 | 0.16 | |
| EBIT | -23.77 | -28.11 | -15.35 | -27.65 | -26.61 | -20.5 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.